Related Experiment Videos
Surgery for intracerebral hemorrhage
1Department of Neurology, Yale University School of Medicine, New Haven, CT 06520-8018, USA.
Insights
Intracerebral hemorrhage (ICH) is a severe stroke type with high mortality and disability rates. Current treatments, including surgery and medical therapies, require further investigation for improved patient outcomes.
Area of Science:
- Neurology
- Neurosurgery
- Vascular Medicine
Background:
- Intracerebral hemorrhage (ICH) accounts for a significant stroke burden, particularly in Asian countries, and carries a higher mortality and disability risk than ischemic stroke.
- Key risk factors include advanced age, hypertension, and amyloid angiopathy, all contributing to arterial wall weakening and rupture.
- The pathological process of ICH is dynamic, with hematoma expansion and neurotoxicity from blood products impacting patient outcomes.
Purpose of the Study:
- To review the current understanding of intracerebral hemorrhage (ICH) pathology, risk factors, and treatment modalities.
- To highlight the controversies and lack of extensive research in ICH management, particularly surgical interventions.
- To emphasize the need for further investigation into both surgical and medical adjuvant therapies for ICH.
Main Methods:
- Review of existing literature on intracerebral hemorrhage (ICH) epidemiology, pathophysiology, and treatment.
- Analysis of current surgical approaches, including open and stereotactic hematoma evacuation.
- Discussion of potential benefits of adjuvant medical therapies, such as neuroprotective agents.
Main Results:
- ICH has a significantly higher mortality rate (2-6x) compared to ischemic stroke, with only 20% of patients achieving independence at 6 months.
- Hematoma expansion occurs in 20-30% of ICH cases within 24 hours, correlating with neurological decline.
- Despite 7,000 annual surgical procedures in the US for hematoma evacuation, their efficacy remains inadequately investigated.
Conclusions:
- Intracerebral hemorrhage (ICH) presents a critical neurosurgical challenge with poor prognoses.
- Current treatment strategies, including surgical evacuation and medical therapies, are not sufficiently supported by robust evidence.
- Further rigorous research is essential to optimize the management of ICH and improve patient outcomes.
Abstract:
Intracerebral hemorrhage (ICH) represents 8 to 15% of all strokes in the United States and 20 to 30% of all strokes in Japan and China. Although ICH represents a relatively small fraction of total strokes, it is a formidable disease, with a 30-day mortality rate two- to sixfold higher than that for ischemic stroke. Furthermore, it is a major cause of disability, with only 20% of patients becoming independent at 6 months. The most common risk factors for ICH are age, hypertension, and amyloid angiopathy, which are associated with damage to and weakening of the arterial/arteriolar wall leading to vessel rupture. The pathology is a dynamic one that continues to evolve over the first few days after onset. In 20 to 30% of ICH, clot volume increases over the first 24 hours and is generally associated with neurologic worsening. The final outcome from ICH is related not only to clot volume, compression, and destruction but also to potential neurotoxicity from the blood degradation products and associated neuronal ischemia. The treatment of ICH has been one of the most controversial and least well-studied areas from a medical or surgical perspective. Surgical treatment has evolved over the years and can be grouped into open and stereotactically guided surgery for hematoma evacuation. Seven thousand operations per year are performed in the United States for hematoma evacuation, although this approach has not been adequately investigated. Adjuvant medical therapies with neuroprotective agents require further investigation and may potentially have additive benefits.